Shares Outstanding (Quarterly) Chart

Historical Shares Outstanding (Quarterly) Data

View and export this data back to 2013. Start Trial.
Date Value
June 30, 2026 154.47M
March 31, 2026 154.22M
December 31, 2025 121.15M
September 30, 2025 116.24M
June 30, 2025 116.22M
March 31, 2025 115.91M
December 31, 2024 115.61M
September 30, 2024 115.21M
June 30, 2024 115.20M
March 31, 2024 113.50M
December 31, 2023 112.22M
September 30, 2023 109.11M
June 30, 2023 94.44M
March 31, 2023 80.49M
December 31, 2022 78.85M
September 30, 2022 77.77M
June 30, 2022 77.70M
March 31, 2022 77.34M
December 31, 2021 76.93M
September 30, 2021 76.58M
June 30, 2021 76.46M
March 31, 2021 73.12M
December 31, 2020 72.51M
September 30, 2020 72.02M
June 30, 2020 71.35M
Date Value
March 31, 2020 70.88M
December 31, 2019 70.37M
September 30, 2019 70.09M
June 30, 2019 69.63M
March 31, 2019 69.34M
December 31, 2018 68.30M
September 30, 2018 67.97M
June 30, 2018 67.74M
March 31, 2018 60.15M
December 31, 2017 59.84M
September 30, 2017 57.95M
June 30, 2017 51.35M
March 31, 2017 51.29M
December 31, 2016 45.81M
September 30, 2016 43.63M
June 30, 2016 43.19M
March 31, 2016 39.14M
December 31, 2015 39.01M
September 30, 2015 38.81M
June 30, 2015 38.22M
March 31, 2015 33.70M
December 31, 2014 33.26M
September 30, 2014 4.624M
June 30, 2014 32.05M
March 31, 2014 33.26M

Shares Outstanding Definition

The volume of stock shares issued by the company and in the hands of the public. This number entails how much is being traded in the open market. A decreasing shares outstanding over time may be the result of company buybacks. Companies frequently make stock buybacks and retire those buybacks as treasury stock.

Read full definition.

Shares Outstanding (Quarterly) Range, Past 5 Years

View Shares Outstanding (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shares Outstanding (Quarterly) Benchmarks

View Shares Outstanding (Quarterly) Benchmarks
Start Trial
Enanta Pharmaceuticals, Inc. 29.12M
ACADIA Pharmaceuticals, Inc. 172.13M
Alnylam Pharmaceuticals, Inc. 133.73M
Anika Therapeutics, Inc. 13.38M
Savara, Inc. 205.40M